Ultragenyx Class Action Lawsuit Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy RARE?
Source: Globenewswire
- Lawsuit Timeline: Robbins Geller announced that purchasers of Ultragenyx (NASDAQ: RARE) common stock must seek lead plaintiff status by April 6, 2026, for shares acquired between August 3, 2023, and December 26, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Allegations Overview: The lawsuit accuses Ultragenyx and its executives of violating the Securities Exchange Act of 1934 by misleading investors about the efficacy of their drug in clinical trials, resulting in significant stock price declines following negative disclosures, indicating serious deficiencies in the company's transparency and information disclosure practices.
- Stock Price Impact: Following the announcements on July 9, 2025, and December 29, 2025, Ultragenyx's stock plummeted by over 25% and 42%, respectively, due to the failure to achieve statistical significance in clinical trials, reflecting a severe erosion of market confidence in the company's future prospects, which could hinder its financing capabilities and investor trust.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, underscoring the importance of legal processes in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.820
Low
35.00
Averages
61.65
High
120.00
Current: 21.820
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical Inc. faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with investors needing to apply as lead plaintiffs by April 6, 2026, indicating heightened legal risks for the company.
- Stock Price Volatility: Following the failure to achieve statistical significance in clinical trials, Ultragenyx's stock plummeted over 25% on July 9, 2025, and over 42% on December 29, 2025, reflecting market pessimism regarding the company's future prospects.
- Research Setbacks: The failure of Ultragenyx's Phase III Orbit and Cosmic studies to meet primary endpoint statistical significance highlights significant setbacks in drug development, potentially undermining market confidence and investor trust.
- Legal Representation Information: Robbins Geller law firm is encouraging affected investors to join the lawsuit, illustrating the dual pressure of legal and financial challenges on the company, which may impact its future fundraising capabilities.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Ultragenyx Pharmaceutical Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc., encouraging those who purchased RARE shares between August 3, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment, which is not required for recovery participation.
- Allegations of Misleading Statements: The complaint alleges that Ultragenyx provided overly positive statements while concealing significant adverse facts about setrusumab's risks, misleading investors about the drug's potential effectiveness in clinical trials.
- Impact of Study Failures: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance, causing the stock price to plummet by approximately 42.32% in one day, from $34.19 to $19.72, severely undermining investor confidence.
- Next Steps for Shareholders: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring their rights are protected.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, focusing on investors who purchased securities between August 3, 2023, and December 26, 2025, highlighting concerns for investor rights.
- Legal Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Direct Contact Channels: Investors can directly contact Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for further legal advice and support regarding their claims.
- Market Impact Anticipation: This investigation may negatively impact Ultragenyx's stock price, prompting investors to monitor developments closely to assess risks and potential losses associated with their investments.
See More
Ultragenyx Faces Class Action Over Misleading Drug Information
- Class Action Notice: The Portnoy Law Firm has advised Ultragenyx Pharmaceutical investors of a class action for those who purchased securities between August 3, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 6, 2026.
- False Statement Allegations: The lawsuit alleges that Ultragenyx misled investors by creating a false impression regarding the efficacy of its drug setrusumab, particularly downplaying the risk that patients in the Phase III Orbit study might not achieve a statistically significant reduction in annualized fracture rate.
- Clinical Trial Risks: Ultragenyx is accused of failing to adequately communicate the risks associated with its Phase III Orbit study results, especially since the Phase II results lacked a placebo control group, potentially misleading investors about the drug's effectiveness and impacting their investment decisions.
- Legal Consultation Opportunity: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights, demonstrating a commitment to supporting investor interests and recovery of losses.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate in the lawsuit.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta, leading investors to have an overly optimistic view of the company's prospects, which impacted their investment decisions.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant failures in the company's drug development efforts and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, and the Schall Law Firm specializes in securities class action lawsuits to assist investors in recovering losses and protecting their rights.
See More
Ultragenyx Class Action Lawsuit Update
- Lawsuit Timeline: Ultragenyx Pharmaceutical Inc. faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with investors needing to apply as lead plaintiffs by April 6, 2026, indicating heightened legal risks for the company.
- Stock Price Volatility: Following the failure to achieve statistical significance in clinical trials, Ultragenyx's stock plummeted over 25% on July 9, 2025, and over 42% on December 29, 2025, reflecting market pessimism regarding the company's future prospects.
- Research Setbacks: The failure of Ultragenyx's Phase III Orbit and Cosmic studies to meet primary endpoint statistical significance highlights significant setbacks in drug development, potentially undermining market confidence and investor trust.
- Legal Representation Information: Robbins Geller law firm is encouraging affected investors to join the lawsuit, illustrating the dual pressure of legal and financial challenges on the company, which may impact its future fundraising capabilities.
See More
Investors Alert: Deadline for Class Action Lawsuits Approaches
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of the class action lawsuit against BlackRock TCP Capital Corp., alleging that from November 6, 2024, to January 23, 2026, the company failed to appropriately value investments, resulting in significant investor losses.
- Mereo BioPharma Lawsuit: The class action against Mereo BioPharma Group plc claims that between June 5, 2023, and December 26, 2025, the company did not disclose material facts regarding setrusumab's statistical significance in the ORBIT and COSMIC studies, impacting investor confidence.
- Pomdoctor Lawsuit: The class action against Pomdoctor Limited alleges involvement in a fraudulent stock promotion scheme through social media misinformation from October 9, 2025, to December 11, 2025, leading to investor losses, with a deadline of April 6, 2026, to apply as lead plaintiff.
- Ultragenyx Lawsuit: The class action against Ultragenyx Pharmaceutical Inc. alleges failure to disclose expected results for its Phase III studies from August 3, 2023, to December 26, 2025, urging investors to act before the April 6, 2026, deadline.
See More
Ultragenyx Pharmaceutical Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Ultragenyx Pharmaceutical Inc., encouraging those who purchased RARE shares between August 3, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment, which is not required for recovery participation.
- Allegations of Misleading Statements: The complaint alleges that Ultragenyx provided overly positive statements while concealing significant adverse facts about setrusumab's risks, misleading investors about the drug's potential effectiveness in clinical trials.
- Impact of Study Failures: On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies failed to achieve statistical significance, causing the stock price to plummet by approximately 42.32% in one day, from $34.19 to $19.72, severely undermining investor confidence.
- Next Steps for Shareholders: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring their rights are protected.
See More
Faruqi & Faruqi Investigates Ultragenyx Securities Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc, focusing on investors who purchased securities between August 3, 2023, and December 26, 2025, highlighting concerns for investor rights.
- Legal Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Direct Contact Channels: Investors can directly contact Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for further legal advice and support regarding their claims.
- Market Impact Anticipation: This investigation may negatively impact Ultragenyx's stock price, prompting investors to monitor developments closely to assess risks and potential losses associated with their investments.
See More
Ultragenyx Faces Class Action Over Misleading Drug Information
- Class Action Notice: The Portnoy Law Firm has advised Ultragenyx Pharmaceutical investors of a class action for those who purchased securities between August 3, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 6, 2026.
- False Statement Allegations: The lawsuit alleges that Ultragenyx misled investors by creating a false impression regarding the efficacy of its drug setrusumab, particularly downplaying the risk that patients in the Phase III Orbit study might not achieve a statistically significant reduction in annualized fracture rate.
- Clinical Trial Risks: Ultragenyx is accused of failing to adequately communicate the risks associated with its Phase III Orbit study results, especially since the Phase II results lacked a placebo control group, potentially misleading investors about the drug's effectiveness and impacting their investment decisions.
- Legal Consultation Opportunity: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights, demonstrating a commitment to supporting investor interests and recovery of losses.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate in the lawsuit.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta, leading investors to have an overly optimistic view of the company's prospects, which impacted their investment decisions.
- Clinical Trial Failure: The Phase III ORBIT study revealed that Ultragenyx failed to achieve a statistically significant reduction in annualized fracture rate, highlighting significant failures in the company's drug development efforts and exacerbating investor losses.
- Legal Consequences: As the market learned the truth about Ultragenyx, investors suffered damages, and the Schall Law Firm specializes in securities class action lawsuits to assist investors in recovering losses and protecting their rights.
See More
